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Introduction: Dynamic proteolysis, through the ubiquitin-proteasome system, has an
important role in DNA transcription and cell cycle, and is considered to modulate
cell stress response and synaptic plasticity. We investigated whether genetic variants
in the ubiquitin carboxyl-terminal hydrolase 46 (USP46) would be associated with
post-traumatic stress disorder (PTSD) in people with exposure to combat trauma using
a case-control candidate gene association design.
Methods: Korean male veterans exposed to the Vietnam War were grouped into those
with (n = 128) and without (n = 128) PTSD. Seven tagging SNPs of USP46 were
selected, and single-marker and haplotype-based association analyses were performed.
All analyses were adjusted for sociodemographic factors and levels of combat exposure
severity and alcohol problem.
Results: One single-marker (rs2244291) showed nominal evidence of association with
PTSD status and with the “re-experiencing” cluster, although the association was not
significant after Bonferroni correction. No significant association with the other SNPs or
the haplotypes was detected.
Conclusion: The present finding suggests preliminarily that genetic vulnerability
regarding the ubiquitin-proteasome system may be related to fear memory processes
and the development of PTSD symptoms after trauma exposure. Further studies with a
larger sample size will be needed to examine the role of the ubiquitin-proteasome system
including USP46 in PTSD.
Keywords: post-traumatic stress disorder, ubiquitin proteasome system, ubiquitin specific peptidase, USP46,
genetic association study
INTRODUCTION
Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition with characteristic
symptoms, including re-experience of fear memory and severe anxiety as long-term responses to
life-threatening traumatic exposure (1). However, not all people who are exposed to trauma develop
PTSD. For instance, only around 10–20% of veterans exposed to combat trauma develop PTSD
(2–4). The reason why certain individuals are more likely to develop PTSD than others after similar
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trauma exposure has not been elucidated. The molecular
determinants of individual differences in vulnerability or
resilience to stressors are still not well-understood. Twin
studies have shown that PTSD is moderately heritable, with
approximately 40% of the variance in PTSD attributable to
genetic variance (5–7). Accummulating evidence shows that
genetic factors contribute to the PTSD susceptibility among
people who have experienced trauma (8, 9).
There is emerging literature on genetic variations in
mechanisms responsible for development and maintenance of
PTSD (9–11). Many studies on detection of candidate genes
associated with PTSD have focused on genetic variations
of the dopaminergic and serotonergic systems (12–15), but
robust common genetic variants have yet to be identified.
Since ubiquitin-proteasome-mediated proteolysis plays a crucial
role in synaptic development and long-term synaptic plasticity
in neural circuits (16–20), the ubiquitin-proteasome system
is an interesting biological target for the pathophysiology
of human neuropsychiatric disorders related to stress-related
synaptic plasticity, such as PTSD. Dynamic and reversible
processes via the ubiquitin-proteasome system regulate synaptic
Alpha-amino-3-hydroxy-5-Methyl-4-isoxazolepropionic acid—
type glutamate receptors (AMPARs) levels, which is known
to be important for controlling development and function of
glutamatergic synapses and long-term potentiation of synaptic
transmission in the brain (21, 22). Substantial evidence from
animal studies suggests that ubiquitin-mediated proteolysis is an
important regulation process for fear memory formation and
reconsolidation (23–26). To date, little is known about the genetic
evidence of the role of ubiquitin-proteasome system in clinical
samples of individuals with PTSD.
Ubiquitin carboxyl-terminal hydrolase 46 (USP46), a
deubiquitinating enzyme that is widely expressed throughout the
brain (19), was identified in Caenorhabditis elegans as the first
deubiquitinating enzyme to regulate degradation of glutamate
receptors and reported to have several roles in the nervous system
(27). In mammalian studies, both in vivo and in vitro, USP46 has
been implicated in regulating the AMPA glutamatergic system
(28, 29), which is important for inter-neuronal communication
and higher brain functions such as learning and memory.
For example, altered AMPAR expression has been shown to
modulate contextual fear memory reconsolidation (30, 31) and
endocytosis of AMPARs has been demonstrated to be required
for the loss of fear response during adaptive reconsolidation of
contextual fear (32). In addition, USP46 has been implicated
in regulating the GABAergic system (33–36), which also has
a crucial role in fear memory formation, reconsolidation, and
extinction (37–42). Notably, Ebihara and colleagues reported
that Usp46 knockout mice display shortened immobility times
in the tail suspension test (36) and long-term memory deficits
Abbreviations: USP46, ubiquitin carboxyl-terminal hydrolase 46; PTSD,
post-traumatic stress disorder; USP, ubiquitin specific peptidase; GABA,
gamma-aminobutyric acid; AMPA, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; VHS, veterans health service; CAPS, clinician-
administered PTSD scale; CES, combat exposure scale; AUDIT, alcohol use
disorders identification test; SNPs, single nucleotide polymorphisms; LD,
linkage disequilibrium.
in the object recognition test (33). They also found out that
Usp46 mutant mice were more sensitive to stress and developed
impaired maternal behaviors (43). The findings on the possible
regulatory role of the USP46 in synaptic plasticity and fear
memory processing suggest that USP46 may be an interesting
candidate for the development and recovery of fear-related
disorders such as PTSD. Although USP46 single nucleotide
polymorphism (SNP) has been reported to be associated with
major depressive disorder (44) and with depressive temperament
(45) in human, no study has been conducted to examine the
association of the USP46 gene with PTSD in a clinical sample.
We investigated whether the genetic variants of the USP46
would be associated with chronic PTSD status in Korean male
veterans with exposure to combat trauma using a case-control
candidate gene association design. Our main hypothesis was
that susceptibility to PTSD might be associated with genetic
polymorphisms of the USP46.
MATERIALS AND METHODS
Participants and Procedure
According to the DSM-IV-TR diagnostic criteria (1) for PTSD,
128 subjects with PTSD and 128 (non-PTSD) controls were
recruited from a psychiatric outpatient clinic at the Veterans
Health Service (VHS) Medical Center. All subjects were of
Korean ethnicity and male veterans who had served on active
duty during the Vietnam War. Individuals with a history of
head trauma, organic brain syndrome including cerebrovascular
accidents or dementia, major psychiatric disorders including
psychosis or bipolar disorder, or substance dependence other
than alcohol and nicotine were excluded. The study was approved
by the institutional review board of the VHS Medical Center,
South Korea (BOHUN 2016-02-007). All subjects gave their
written informed consent before participating in this study.
Measures
For assessing PTSD, we used the Clinician-Administered PTSD
Scale (CAPS), a structured clinical interview, which is considered
the gold standard for diagnosing PTSD (46, 47). The diagnosis
of PTSD was determined by symptom frequency and intensity
based on the liberal scoring rule of the CAPS (48). In addition,
the Combat Exposure Scale (CES), a self-reporting scale, was
administered for measuring the level of wartime traumatic
stressors experienced by the combatants (49). The total CES
scores were divided into five categories of combat exposure:
light (1–8), light–moderate (9–16), moderate (17–24), moderate–
heavy (25–32), and heavy (33–41). The Alcohol Use Disorders
Identification Test (AUDIT) was also used to assess hazardous
and harmful alcohol use (50).
Genotyping
Seven tagging SNPs covering all regions of USP46 (rs346005,
rs10034164, rs2244291, rs12646800, rs6554557, rs17675844, and
rs10517263) were selected with the criteria of an r2 threshold
>0.8 based on a prior genetic association study in a Japanese
population in which gene-based approach was used involving
all common SNPs (minor allele frequency >5%) (44). Subjects
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donated a blood sample through venipuncture, and the DNA
of each subject was isolated using extraction protocol with
QG-810/800 of Quickgene DNA whole blood kit-S after lysate
preparation. The genotyping procedures were carried out using
single base primer extension assay using the ABI PRISM
SNaPShot multiplex kit (ABI, Foster City, CA, USA) according to
the manufacturer’s recommendations. The forward and reverse
primer pairs used for the SNaPshot assay and genetic information
for all tested SNPs are presented in Supplementary Table 1.
Analysis was performed using Genemapper software (version 3.0;
Applied Biosystems) in the DNA Link, Inc. (Seoul, South Korea).
Data Analyses
Demographic and clinical characteristics between subjects with
and without PTSD were compared using χ2-test or Student’s
t-test on the Statistical Package for the Social Sciences version
25.0 (SPSS Inc., Chicago, IL, USA). The Hardy–Weinberg
equilibrium for each SNP in the control group was calculated
by χ2-test. Statistical power was calculated with Genetic
Association Study Power Calculator (https://csg.sph.umich.edu/
abecasis/gas_power_calculator). Given the available sample size,
the statistical power for detecting a risk allele with an effect size
of 1.6 is 88%, depending on 10% minor allele frequency, 40%
lifetime disease prevalence of war veterans, and 5% alpha level.
Single-marker analyses were performed using the R package
SNPassoc (51). Between-group comparisons of genotype
frequency differences for diagnostic status were performed
by logistic regression analysis considering different genetic
inheritance models. For five SNPs whose genotype frequencies
of homozygous with minor alleles were <5%, dominant genetic
model was assumed. The outcome variable was analyzed yielding
odds ratios (ORs) with 95% confidence intervals (CIs) and
p-values. Associations between haplotype distributions and
PTSD status were examined using the “haplo.score” function
of R package haplo.stats (52). This package computes score
statistics to test associations between haplotypes and a trait
allowing adjustment for other determinants. This analysis
was corrected for multiple testing by applying the simulate =
TRUE parameter in haplo.score which gives simulated p-values.
These simulated haplotype score statistics are calculated from
a permuted re-ordering of the trait (PTSD status) and USP46
polymorphisms. We used 100,000 permutations for all the
analyses. Haploblock structure and linkage disequilibrium
(LD) patterns obtained from the seven SNPs were constructed
using the Haploview ver.4.2 (http://www.broad.mit.edu/mpg/
haploview). In further analysis, we conducted linear regression
analyses for three clusters (re-experiencing, avoidance, and
hyperarousal) of PTSD symptoms considering PTSD as
continuous phenotypes. Demographic and clinical characteristics
which were different between cases and controls in χ2-test or
t-test (p < 0.1) or which have been reported as a risk factor of
PTSD in previous studies (53, 54) were selected as potential
confounders in analyses. As a result, all analyses were adjusted
for demographic factors including age, education year, socio-
economic status, and marital status; the five levels of CES, and
AUDIT scores (harmful alcohol drinking). In all analyses, p-value
of <0.05 was considered as nominally significant (uncorrected





T or χ2 P-value
Age 62.92 ± 4.32 63.15 ± 3.55 0.46 0.647
Education (years) 10.53 ± 3.12 10.38 ± 2.83 −0.40 0.690
Marital status:
Married/others, n 119/9 110/18 3.35 0.067
Socioeconomic status:





38/48/30/11/1 6/29/60/26/7 48.54 <0.001
AUDIT score 6.84 ± 7.53 11.66 ± 10.92 4.11 <0.001
Total CAPS 8.84 ± 11.39 62.85 ± 22.27 24.42 <0.001
Re-experiencing 4.16 ± 7.38 20.72 ± 8.56 16.58 0.001
Avoidance 1.57 ± 3.34 21.46 ± 10.18 21.00 <0.001
Hyperarousal 3.19 ± 4.18 20.67 ± 8.15 17.48 <0.001
p < 0.05). The statistical threshold was corrected using the
Bonferroni method for the total number of SNPs (α = 0.05/7
= 0.0071).
RESULTS
The demographic and clinical characteristics of subjects with
and without PTSD are presented in Table 1. The groups with
and without PTSD were not significantly different in terms of
age, education level, marital status, and socioeconomic status.
For combat exposure, the distribution of the five CES categories
showed a significant difference between PTSD and non-PTSD
groups (χ2 = 48.54, df = 4, p < 0.001), with a higher proportion
of heavy trauma experience in subjects with PTSD than those
without PTSD. For alcohol problem, subjects with PTSD had
significantly harmful alcohol consumption based on the AUDIT
score, compared to those without PTSD (11.66 ± 10.92 vs. 6.84
± 7.53, p < 0.001).
The allelic distributions of the seven SNPs in the control
group were in accordance with the Hardy–Weinberg equilibrium
(Supplementary Table 2). In single-marker analyses under
multiple genetic models, only one single-marker (rs2244291)
showed a significant association at the nominal significance level
of 5% (p = 0.0193 in over-dominant model and p = 0.0497
in Co-dominant model), but the association did not remain
significant after stringent correction for multiple comparisons
(Table 2). For the other SNPs in the USP46 region, no significant
association was found between the groups (Table 2).
The analysis of LD and haplotype block for the USP46
revealed one haplotype block (Figure 1). In haplotype analyses,
the permutation test of the seven SNP haplotypes showed
no significant difference in the estimated haplotype frequency
distributions between both groups (Table 3).
In further analyses considering PTSD as continuous
phenotypes, the rs2244291, which was shown to be nominally
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TABLE 2 | Association of the USP46 SNPs under different genetic models with PTSD status.
SNP Model Genotype Non-PTSD PTSD OR(95% CI) P-value AIC
rs346005 Co-dominant A/A 42 (35.9%) 35 (29.9%) 1.00 0.4781 279.1
A/C 49 (41.9%) 61 (52.1%) 1.33 (0.67–2.65)
C/C 26 (22.2%) 21 (17.9%) 0.84 (0.36–1.96)
Dominant A/A 42 (35.9%) 35 (29.9%) 1.00 0.6570 278.4
A/C–C/C 75 (64.1%) 82 (70.1%) 1.16 (0.61–2.19)
Recessive A/A–A/C 91 (77.8%) 96 (82.1%) 1.00 0.3719 277.8
C/C 26 (22.2%) 21 (17.9%) 0.71 (0.34–1.50)
Over-dominant A/A–C/C 68 (58.1%) 56 (47.9%) 1.00 0.2504 277.3
A/C 49 (41.9%) 61 (52.1%) 1.42 (0.78–2.60)
Log-additive – 117 (50.0%) 117 (50.0%) 0.96 (0.63–1.45) 0.8312 278.6
rs10034164 Co-dominant T/T 85 (71.4%) 87 (73.7%) 1.00 0.3382 283.2
C/T 31 (26.1%) 26 (22.0%) 0.59 (0.29–1.21)
C/C 3 (2.5%) 5 (4.2%) 1.05 (0.21–5.18)
Dominant T/T 85 (71.4%) 87 (73.7%) 1.00 0.1926 281.7
C/T–C/C 34 (28.6%) 31 (26.3%) 0.64 (0.32–1.26)
Recessive T/T–C/T 116 (97.5%) 113 (95.8%) 1.00 0.8017 283.4
C/C 3 (2.5%) 5 (4.2%) 1.22 (0.25–5.90)
Over-dominant T/T–C/C 88 (73.9%) 92 (78.0%) 1.00 0.1412 281.3
C/T 31 (26.1%) 26 (22.0%) 0.59 (0.29–1.20)
Log-additive – 119 (50.2%) 118 (49.8%) 0.75 (0.43–1.32) 0.3227 282.4
rs2244291 Co-dominant A/A 86 (67.2%) 73 (57.0%) 1.00 *0.0497 307.1
A/G 33 (25.8%) 50 (39.1%) 1.95 (1.06–3.59)
G/G 9 (7.0%) 5 (3.9%) 0.61 (0.16–2.32)
Dominant A/A 86 (67.2%) 73 (57.0%) 1.00 0.0765 308.0
A/G–G/G 42 (32.8%) 55 (43.0%) 1.68 (0.94–3.00)
Recessive A/A–A/G 119 (93.0%) 123 (96.1%) 1.00 0.2613 309.9
G/G 9 (7.0%) 5 (3.9%) 0.48 (0.13–1.77)
Over-dominant A/A–G/G 95 (74.2%) 78 (60.9%) 1.00 *0.0193 305.6
A/G 33 (25.8%) 50 (39.1%) 2.03 (1.11–3.69)
Log-additive – 128 (50.0%) 128 (50.0%) 1.29 (0.80–2.07) 0.2952 310.0
rs12646800 Co-dominant C/C 107 (89.9%) 102 (86.4%) 1.00 0.7025 283.3
C/T 12 (10.1%) 16 (13.6%) 1.20 (0.47–3.10)
Log-additive – 119 (50.2%) 118 (49.8%) 1.20 (0.47–3.10) 0.7025 283.3
rs6554557 Co-dominant A/A 85 (71.4%) 86 (73.5%) 1.00 0.3471 281.3
A/C 31 (26.1%) 27 (23.1%) 0.59 (0.29–1.22)
C/C 3 (2.5%) 4 (3.4%) 0.69 (0.13–3.69)
Dominant A/A 85 (71.4%) 86 (73.5%) 1.00 0.1484 279.4
A/C–C/C 34 (28.6%) 31 (26.5%) 0.60 (0.30–1.20)
Recessive A/A–A/C 116 (97.5%) 113 (96.6%) 1.00 0.8020 281.4
C/C 3 (2.5%) 4 (3.4%) 0.81 (0.15–4.24)
Over-dominant A/A–C/C 88 (73.9%) 90 (76.9%) 1.00 0.1650 279.5
A/C 31 (26.1%) 27 (23.1%) 0.61 (0.30–1.24)
Log-additive – 119 (50.4%) 117 (49.6%) 0.68 (0.38–1.21) 0.1911 279.7
rs17675844 Co-dominant A/A 101 (86.3%) 94 (81.7%) 1.00 0.2047 276.3
C/A 15 (12.8%) 20 (17.4%) 2.13 (0.92–4.91)
C/C 1 (0.9%) 1 (0.9%) 1.02 (0.03–35.28)
Dominant A/A 101 (86.3%) 94 (81.7%) 1.00 0.0825 274.5
C/A–C/C 16 (13.7%) 21 (18.3%) 2.05 (0.91–4.64)
Recessive A/A–C/A 116 (99.1%) 114 (99.1%) 1.00 0.9888 277.5
C/C 1 (0.9%) 1 (0.9%) 0.98 (0.03–33.44)
(Continued)
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TABLE 2 | Continued
SNP Model Genotype Non-PTSD PTSD OR(95% CI) P-value AIC
Over-dominant A/A–C/C 102 (87.2%) 95 (82.6%) 1.00 0.0749 274.3
C/A 15 (12.8%) 20 (17.4%) 2.08 (0.92–4.91)
Log-additive – 117 (50.4%) 115 (49.6%) 1.86 (0.87–4.00) 0.1061 274.9
rs10517263 Co-dominant C/C 93 (78.8%) 97 (82.2%) 1.00 0.3338 281.7
G/C 24 (20.3%) 20 (16.9%) 0.56 (0.25–1.23)
G/G 1 (0.8%) 1 (0.8%) 0.65 (0.04–11.49)
Dominant C/C 93 (78.8%) 97 (82.2%) 1.00 0.1394 279.7
G/C–G/G 25 (21.2%) 21 (17.8%) 0.56 (0.26–1.22)
Recessive C/C–G/C 117 (99.2%) 117 (99.2%) 1.00 0.8291 281.8
G/G 1 (0.8%) 1 (0.8%) 0.73 (0.04–12.88)
Over-dominant C/C–G/G 94 (79.7%) 98 (83.1%) 1.00 0.1467 279.8
G/C 24 (20.3%) 20 (16.9%) 0.56 (0.25–1.23)
Log-additive – 118 (50.0%) 118 (50.0%) 0.60 (0.30–1.23) 0.1579 279.9
OR, odds ratio; CI, confidence interval; AIC, akaike information criterion of each genetic model.
*p < 0.05.
FIGURE 1 | Haploblock structure and linkage disequilibrium for the non-PTSD group from tagging SNPs of USP46. The color scheme is based on r2-value (left) and D
prime value (right).
significantly associated with PTSD status in the main analysis,
was associated with the “re-experiencing” cluster of PTSD
symptoms (p = 0.014 in over-dominant model and p= 0.041 in
co-dominant model) (Table 4).
DISCUSSION
The present study examined a genetic association between
the USP46 genetic variants and chronic PTSD among Korean
male combat veterans. Single-marker analysis resulted in a
nominally significant association only for rs2244291 with PTSD
status, although the association did not remain significant after
stringent correction for multiple comparisons. In addition,
the rs2244291 was found to be associated with the “re-
experiencing” cluster of PTSD symptoms. The present finding
suggests preliminarily that some underlying genetic vulnerability
regarding the ubiquitin-proteasome system such as USP46 may
be related to fearmemory processes and the development of some
PTSD symptoms after trauma exposure.
To the best of our knowledge, the present study is the
first to investigate the possible genetic association of the
deubiquitinating enzyme in genetic susceptibility for PTSD.
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TABLE 3 | The effects of USP46 Haplotype on the affected status of PTSD.
Block 1a Hap-Freqb Hap-Scorec Crude p-vald Sim. p-vale
rs346005 rs10034164 rs2244291 rs12646800 rs6554557 rs17675844 rs10517263
C C A C C A G 0.0997 −1.3480 0.1777 0.1856
C T A C A A C 0.0718 −1.1957 0.2318 0.2389
C T G C A A C 0.1284 0.1278 0.8983 0.9007
A T A C A A C 0.5052 0.2355 0.8138 0.8148
C C A C C A C 0.0514 0.3377 0.7356 0.7417
A T A T A A C 0.0521 0.3821 0.7024 0.7084
C T G C A C C 0.0845 1.3005 0.1934 0.1996
aGlobal-stat = 4.91724, df = 7, p = 0.67006, global simulated p = 0.69839.
bHap-Freq, estimated frequency of the haplotype in the pool of all participants.
cHap-Score, score for the haplotype.
dAsymptotic chi-square p-value.
eSimulated p-value.
TABLE 4 | The effects of USP46 rs2244291 on three clusters of PTSD symptom.
Cluster Model Genotype n Mean (S.E) Mean difference
(95% CI)
p-value AIC
Re-experiencing A/A 159 11.56(0.09)
Co-dominant A/G 83 14.71(1.32) 3.10(0.50 to 5.70) 0.041* 1902
G/G 14 8.93(2.90) −1.54(−6.91 to 3.83)
Dominant A/A 159 11.56(0.89) 0.054 1902
A/G–G/G 97 13.88(1.21) 2.46(−0.03 to 4.95)
Recessive A/A–A/G 242 12.64(0.74) 0.326 1905
G/G 14 8.93(2.90) −2.68(−8.02 to 2.66)
Over-dominant A/A–G/G 173 11.35(0.85) 0.014* 1900
A/G 83 14.71(1.32) 3.24(0.68 to 5.79)
Log-additive – – – 1.25(−0.80 to 3.29) 0.234 1905
Avoidance Co-dominant A/A 159 11.04(1.01) 0.603 1986
A/G 83 12.69(1.34) 1.45(−1.62 to 4.51)
G/G 14 9.93(3.29) −0.73(−7.06 to 5.61)
Dominant A/A 159 11.04(1.01) 0.443 1984
A/G–G/G 97 12.29(1.24) 1.14(−1.78 to 4.07)
Recessive A/A–A/G 242 11.61(0.81) 0.693 1985
G/G 14 9.93(3.29) −1.26(−7.49 to 4.98)
Over-dominant A/A–G/G 173 10.95(0.96) 0.326 1984
A/G 83 12.69(1.34) 1.51(−1.50 to 4.52)
Log-additive – – – 0.58(−1.81 to 2.97) 0.635 1985
Hyperarousal Co-dominant A/A 159 11.36(0.87) 0.407 1903
A/G 83 13.06(1.15) 1.77(−0.84 to 4.38)
G/G 14 11.71(3.30) 1.12(−4.27 to 6.51)
Dominant A/A 159 11.36(0.87) 0.186 1901
A/G–G/G 97 12.87(1.09) 1.68(−0.80 to 4.17)
Recessive A/A–A/G 242 11.94(0.70) 0.862 1903
G/G 14 11.71(3.30) 0.47(−4.84 to 5.78)
Over-dominant A/A–G/G 173 11.39(0.84) 0.201 1902
A/G 83 13.06(1.15) 1.68(−0.89 to 4.24)
Log-additive – – – 1.19(−0.84 to 3.22) 0.252 1902
Cluster, PTSD symptom cluster; S.E, standard errors for each genotype; CI, confidence interval; AIC, Akaike information criterion of each genetic model; *p < 0.05.
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There is indirect evidence supporting the role of USP46 in
PTSD and fear memory processes. In animal studies, Ebihara and
colleagues suggested thatUsp46might be a quantitative trait gene
responsible for immobility time reflecting behavioral despair
under inescapable stress conditions (34). They showed that
Usp46 knockout mice exhibited shorter immobility times in the
tail-suspension test, assessing depression-like behavior; reduced
sucrose consumption in the sucrose preference test, assessing
anhedonia-like symptoms; and lower locomotor activity levels
in the open field test, assessing exploratory behavior and
anxiety compared to wild type mice (33), which suggests the
involvement of Usp46 in stress-related phenotypes. In addition,
ubiquitin-mediated protein degradation has been shown as
important regulatory process in consolidation and extinction
of memory in animal studies (23, 55, 56). Recent in vitro and
in vivo findings showed that USP46 regulates glutamatergic
receptor ubiquitination and turnover, as well as the strength
of synaptic transmission, which suggest the involvement of
USP46 in synaptic plasticity and fear memory processes (29,
57). These findings are compatible with our finding that
the USP46 rs2244291 is associated with the “re-experiencing
(having sudden and intrusive traumatic memories)” cluster,
the core PTSD symptom, although fear memory processes
themselves were not evaluated in the current study, when
considering that re-experiencing of the traumatic event is closely
related with abnormalities in fear memory processes including
conditioning, reconsolidation and extinction of fear memory
(58, 59). Particularly, rs2244291 has been reported to be involved
in a haplotype pattern of susceptibility to major depression in
a Japanese population by Fukuo et al. (44). Substantial genetic
overlap between PTSD and depression has been reported (6, 60),
which implies that genes implicated in the pathophysiology of
depression are candidates for PTSD. When considering shared
genetic components between PTSD and depression, genetic
variations of ubiquitin-proteasome system, such as rs2244291,
may be involved in regulating dynamic and reversible processes
in synaptic plasticity and long-term potentiation after stress
exposures in stress-related conditions, rather than in a disease-
specific manner.
However, since no significant association with PTSD for the
SNPs or the haplotype in the USP46 region was detected after
stringent correction for multiple comparisons in this Korean
population, the present findings should be interpreted cautiously
and preliminarily until confirmed. One possible reason for a weak
association is that any one genetic polymorphism may confer
a small genetic contribution to PTSD due to multi-factorial
polygenic involvement in the pathophysiology of PTSD. The
present negative findings in the main analysis should not be
interpreted as conclusive for no association because the present
sample might be too small for adequate statistical power to detect
genetic variants with extremely small effect. Another possibility
is that the weak association might be related to functional
impact of other potential unmeasured genetic factors, such as the
role of rare and structural genetic variations with strong effect.
Although the role of rare and structural variation is not known in
PTSD (61), rare variants were found to play unique roles in the
genetics of complex diseases and research of rare variants require
larger sample sizes than common variants to ensure sufficient
statistical power (62). Further genetic studies in much larger
samples will be helpful in unraveling the genetic contribution
of common variants and rare variants to PTSD, its clusters, and
broader phenotypes.
The strength of the present genetic association study is
that case (trauma-exposed PTSD subjects)—control (trauma-
exposed non-PTSD controls) design was applied for a relatively
homogenous sample with exposure to similar trauma in a racially
uniform population. However, limitations of this study should
be noted. First, environmental factors such as early-life trauma
were not controlled. Considering possible gene–environment
interactions, some environments may have confounding effects
that influence chronic PTSD status. Second, although our
subjects are likely to comprise a more homogeneous sample
with similar age and a single ethnic origin, the present study
can only be regarded as a preliminary study in the Korean
elderly population. Therefore, it should be replicated in larger
sample sets, including populations with diverse ages and different
ethnic backgrounds. Third, although we selected the USP46 as a
candidate gene based on a priori hypothesis on the possible role
of the USP46 in synaptic plasticity and fear memory formation
from previous studies, the functions of the present seven tag SNPs
are unknown and no evidence of USP46 has been reported from
the GWAS studies on PTSD. Fourth, copy number variants or
rare variants of USP46 were not examined. In addition, gene
expression analysis of the USP46 was not conducted. Finally,
psychiatric comorbidities such as depression might affect the
present results. Since comorbidity of PTSD and depression could
be largely explained by common genetic influences (60), we did
not exclude the comorbidities. In the context of common genetic
liability among PTSD, anxiety disorders, and depression, further
research is required to determine genetic and environmental
factors that influence the development of PTSD.
In summary, we investigated the clinical relevance of the
genetic factors in the USP46 using a case-control association
design in Korean male veterans with or without PTSD after
exposure to combat trauma. While the present findings suggest
preliminarily that USP46 rs2244291 may potentially be involved
in re-experiencing symptoms and PTSD status after exposure to
traumatic events, the limited sample size warrants caution for
over-interpreting nominally significant genetic findings. Further
research in large cohorts is needed to better understand the
role of ubiquitin-proteasome system in genetic susceptibility
to PTSD.
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